Published: 25 April 2022
Author(s): Sergi Yun, Cristina Enjuanes, Esther Calero-Molina, Encarnación Hidalgo, Núria José-Bazán, Marta Ruiz, José María Verdú-Rotellar, Paloma Garcimartín, Santiago Jiménez-Marrero, Alberto Garay, Mar Ras, Raúl Ramos, Alexandra Pons-Riverola, Pedro Moliner, Xavier Corbella, Josep Comín-Colet
Issue: July 2022
Section: Original article

Notwithstanding new pharmacological and non-pharmacological approaches, such as optimising care using new monitoring strategies,[1,2] heart failure (HF) remains a huge public health problem worldwide with increased morbidity and mortality [3,4]. Moreover, HF is associated to impaired health-related quality of life (QoL) and high healthcare costs, mainly due to hospital admissions [5–8]. Therefore, prevention-targeted and integrated disease management approaches focused on the early post-discharge period, the so-called ‘vulnerable phase’, where a higher proportion of events in HF patients are concentrated, have been assessed and deployed in recent years [9–11].


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.